Shares of blue-chip pharmaceutical company Merck (NYSE: MRK ) have been clobbered (in big pharma terms) since reporting earnings on Friday. With the stock down more than 5% since that report, some investors might be looking to take action.
In the video below, health care bureau chief Brenton Flynn offers his opinion of Merck today, and whether investors should take the money and run -- or back up the truck and buy more.
For nearly 100 years, Merck's cutting-edge research has led to a number of medical breakthroughs. Today, however, this pharma stalwart is staring down a steep patent cliff and facing generic competition for its top-selling drug. To find out if this pharma giant has the stamina to keep its Bunsen burners alight, grab your copy of our brand new premium research report today. Our senior biotech analyst Brian Orelli, Ph.D., walks you through both the opportunities and threats facing Merck, and the report comes with a full 12 months of updates. Claim your copy now by clicking here.